Monthly Archives: November 2012
FDA Already Knew of Problems at New England Compounding Center
By Amy Ritter.
In the wake of the meningitis outbreak caused by contaminated compounded medications produced by the New England Compounding Center (NECC), both the government and the public have been wrestling with the question of how this happened — how did a company producing substandard medicines slip through regulatory oversight?
Posted in Guest Blog, Regulatory Tagged FDA, House Energy and Commerce Committee, NECC, New England Compunding Center Leave a comment
With the Election Decided, It's Full Speed Ahead on ObamaCare
by Tom Norton
With the Presidential election decided and President Obama the clear winner, it’s time for Pharma to get down to business on the implementation of ObamaCare. Here are some of the key actions to anticipate between now and January 1, 2013.
Posted in FDA, Legal, Regulatory, Strategy, healthcare Tagged Affordable Care Act, HHS, Medicare, Obamacare, Presidential election, Regulatory, US election 3 Comments
Pharmacists: The Other White Coats
Patients in search of face time with a healthcare provider are stopping into their local drugstores, where consultations are free and the wait time is shorter. Pharmacists are in a unique position, too, to move the needle on drug adherence.

Pharma Throws Greece Another Lifeline. Will Greece Reciprocate?